Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models.
Jashdeep BhattacharjeeGraham BeatonSatheesh B RavulaSuk Joong LeeKevin B BaconCelia P JenkinsonMikako WarrenFabio C TucciRohit KohliPublished in: Hepatology communications (2023)
EPGN2154 demonstrated a hepato-protective effect independent of body weight loss in preclinical NASH models.